As COVID-19 infections rise again with the return of school, uncertainty looms over the availability of updated vaccines. Will high-risk individuals be the only ones to access them by mid-September?
Dr. Vinay Prasad is back at the FDA's Center for Biologics Evaluation and Research, raising eyebrows after being ousted amid political turmoil and criticism. His return ignites debates about drug approvals and public health leadership under the Trump administration.
A shooting at the CDC in Atlanta left one police officer dead and raised fears among public health officials. As investigations continue, questions about the suspect's motives emerge, with ties to anti-vaccine sentiments.
A police officer was fatally wounded during a shooting outside the CDC. The shooter is dead, and initial reports suggest a possible link to mental health issues related to a vaccine. Details are unfolding.
The NB.1.8.1 variant of COVID-19 is rapidly spreading in the U.S., now accounting for 37% of cases. Experts warn it may lead to a summer surge, although its severity remains uncertain.
A new COVID-19 variant, NB.1.8.1, is spreading quickly in California, leading health experts to warn of a potential summer surge. Learn about the symptoms, vaccine effectiveness, and what residents should know.
The U.S. has approved Moderna's new COVID-19 vaccine, mNexspike, specifically for high-risk groups. This innovative option offers a lower dose while maintaining effectiveness, marking a pivotal step in the fight against coronavirus.
The FDA has finally approved Novavax’s COVID-19 vaccine, but with unexpected restrictions that could impact its rollout. Discover what this means for public health and vaccination strategies.
The U.S. Department of Health and Human Services is on a bold mission to develop a universal flu vaccine within four years, a project that could revolutionize how we combat influenza and prepare for future pandemics. Funded by $500 million, this initiative aims for FDA approval by 2029, with clinical trials starting soon. Experts weigh in on the challenges and potential of this ambitious project.
Peter Marks, the FDA's Center for Biologics Evaluation and Research head, resigns amid growing concerns over measles outbreaks and vaccine misinformation. His exit raises alarms about future public health initiatives.
